DE10311065A1 - Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung - Google Patents

Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung Download PDF

Info

Publication number
DE10311065A1
DE10311065A1 DE2003111065 DE10311065A DE10311065A1 DE 10311065 A1 DE10311065 A1 DE 10311065A1 DE 2003111065 DE2003111065 DE 2003111065 DE 10311065 A DE10311065 A DE 10311065A DE 10311065 A1 DE10311065 A1 DE 10311065A1
Authority
DE
Germany
Prior art keywords
alkyl
phenyl
halogen
butyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE2003111065
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Priority to DE2003111065 priority Critical patent/DE10311065A1/de
Priority to AT04719974T priority patent/ATE384052T1/de
Priority to DE502004005959T priority patent/DE502004005959D1/de
Priority to US10/548,931 priority patent/US8008488B2/en
Priority to PCT/EP2004/002609 priority patent/WO2004080981A1/fr
Priority to EP04719974A priority patent/EP1601659B1/fr
Priority to ES04719974T priority patent/ES2299826T3/es
Publication of DE10311065A1 publication Critical patent/DE10311065A1/de
Priority to HK06106239A priority patent/HK1086267A1/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2003111065 2003-03-13 2003-03-13 Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung Withdrawn DE10311065A1 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE2003111065 DE10311065A1 (de) 2003-03-13 2003-03-13 Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
AT04719974T ATE384052T1 (de) 2003-03-13 2004-03-12 Pyrimidin-2-on-verbindungen und ihre verwendung als dopamin-d3-rezeptorliganden
DE502004005959T DE502004005959D1 (de) 2003-03-13 2004-03-12 Pyrimidin-2-on-verbindungen und ihre verwendung als dopamin-d3-rezeptorliganden
US10/548,931 US8008488B2 (en) 2003-03-13 2004-03-12 Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands
PCT/EP2004/002609 WO2004080981A1 (fr) 2003-03-13 2004-03-12 Composes de pyrimidin-2-one et leur utilisation en tant que ligands du recepteur de la dopamine d3
EP04719974A EP1601659B1 (fr) 2003-03-13 2004-03-12 Composes de pyrimidin-2-one et leur utilisation en tant que ligands du recepteur de la dopamine d3
ES04719974T ES2299826T3 (es) 2003-03-13 2004-03-12 Compuestos pirimidin-2-ona y su uso como ligandos del receptor de3 de dopamina.
HK06106239A HK1086267A1 (en) 2003-03-13 2006-05-29 Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2003111065 DE10311065A1 (de) 2003-03-13 2003-03-13 Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung

Publications (1)

Publication Number Publication Date
DE10311065A1 true DE10311065A1 (de) 2004-09-23

Family

ID=32892147

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2003111065 Withdrawn DE10311065A1 (de) 2003-03-13 2003-03-13 Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
DE502004005959T Expired - Lifetime DE502004005959D1 (de) 2003-03-13 2004-03-12 Pyrimidin-2-on-verbindungen und ihre verwendung als dopamin-d3-rezeptorliganden

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502004005959T Expired - Lifetime DE502004005959D1 (de) 2003-03-13 2004-03-12 Pyrimidin-2-on-verbindungen und ihre verwendung als dopamin-d3-rezeptorliganden

Country Status (7)

Country Link
US (1) US8008488B2 (fr)
EP (1) EP1601659B1 (fr)
AT (1) ATE384052T1 (fr)
DE (2) DE10311065A1 (fr)
ES (1) ES2299826T3 (fr)
HK (1) HK1086267A1 (fr)
WO (1) WO2004080981A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014059265A1 (fr) 2012-10-11 2014-04-17 Southern Research Institute Dérivés urée et amide d'aminoalkylpipérazines et leur utilisation

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259382A1 (de) * 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
AU2004259358B2 (en) 2003-07-24 2008-03-20 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
DE102004027359A1 (de) * 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
WO2006015842A1 (fr) * 2004-08-09 2006-02-16 Abbott Gmbh & Co. Kg Composés de 4-pipérazinylpyrimidine convenant pour traiter des troubles qui répondent à une modulation du récepteur d3 de la dopamine
DE102004061593A1 (de) * 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
US20060281076A1 (en) * 2005-05-18 2006-12-14 Nanosphere, Inc. Substrate functionalization method for high sensitivity applications
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
EP2007751B1 (fr) 2006-04-03 2013-08-21 Glaxo Group Limited Dérivés d'azabicyclo [3. 1. 0] hexyle utilisés comme modulateurs des récepteurs de la dopamine d3
JP5189074B2 (ja) * 2006-04-03 2013-04-24 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2685266C (fr) 2007-04-27 2014-01-28 Purdue Pharma L.P. Antagonistes de trpv1 et leurs utilisations dans le traitement ou la prevention de la douleur, de l'iu, ainsi que des ulceres, des maladies inflammatoires chroniques de l'intestin ou du colon irritable chez un animal
DK2200985T3 (da) 2007-09-14 2011-10-24 Ortho Mcneil Janssen Pharm 1,3-Disubstituerede 4-(aryl--X-phenyl)-1H-pyridin-2-oner
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
MX2010002537A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-fenil-1h-piridin-2-onas 1,3-disubstituidas.
GB0719235D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
PA8802101A1 (es) 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2010025890A1 (fr) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Dérivés de 3-azabicyclo[3.1.0]hexyle comme modulateurs des récepteurs métabotropiques du glutamate
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
KR101753826B1 (ko) 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,２,４―트리아졸로［４,３―ａ］피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2661435B1 (fr) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. Dérivés 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
WO2012062750A1 (fr) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. Dérivés de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
PL2723732T3 (pl) 2011-06-22 2017-07-31 Purdue Pharma Lp Antagoniści trpv1 z podstawnikiem dihydroksylowym oraz ich zastosowania
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
AR095264A1 (es) 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
EA033889B1 (ru) 2014-01-21 2019-12-05 Янссен Фармацевтика Нв Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа
KR20230005854A (ko) * 2020-04-02 2023-01-10 써던 리서취 인스티튜트 알파바이러스에 대한 강력한 항바이러스제로서의 새로운 2-피리미돈 유사체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
US5859014A (en) * 1995-06-09 1999-01-12 Syntex (U.S.A.) Inc. Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists
ATE201016T1 (de) * 1995-06-09 2001-05-15 Hoffmann La Roche Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten
DE10131543A1 (de) 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014059265A1 (fr) 2012-10-11 2014-04-17 Southern Research Institute Dérivés urée et amide d'aminoalkylpipérazines et leur utilisation

Also Published As

Publication number Publication date
WO2004080981A1 (fr) 2004-09-23
DE502004005959D1 (de) 2008-03-06
EP1601659B1 (fr) 2008-01-16
US20060235004A1 (en) 2006-10-19
US8008488B2 (en) 2011-08-30
ATE384052T1 (de) 2008-02-15
HK1086267A1 (en) 2006-09-15
EP1601659A1 (fr) 2005-12-07
ES2299826T3 (es) 2008-06-01

Similar Documents

Publication Publication Date Title
DE10311065A1 (de) Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
EP1828146B1 (fr) Composes n-heterocycliques substitues et leur utilisation comme ligands du recepteur de la dopamine d3
EP1763522A1 (fr) Composes pyridin-2-one et leur utilisation en tant que modulateurs du recepteur d3 de la dopamine
EP0877744B1 (fr) Composes aza- et diazacycloheptane et -cyclo-octane substitues et leur utilisation
EP0772603A1 (fr) Composes substitues de pyrimidine et leur utilisation
EP0772604A1 (fr) Composes triazole et leur utilisation comme ligands de la dopamine-d 3?
US6919342B2 (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
EP1751116B1 (fr) Composés de pyrimidine et leur utilisation dans le traitement d' affections liées au système nerveux central
KR20100094491A (ko) 도파민 ｄ3 수용체의 조절에 반응하는 장애의 치료를 위한 １，２，４－트리아진－３，５－디온 화합물
DE602004000158T2 (de) Triazole für die Behandlung von auf die Modulation des Dopamin D3 Rezeptors ansprechende Krankheiten
EP1594861B1 (fr) Composes de triazole et utilisation therapeutique desdits composes
DE10131543A1 (de) Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
DE69115954T2 (de) Kondensierte 7-gliedrige zyklische Verbindungen und diese enthaltende antipsychotische Zubereitung
EP2203426B1 (fr) Composés de benzènesulfonamide appropriés pour le traitement de troubles qui répondent à une modulation du récepteur d<sb>3</sb>de la dopamine

Legal Events

Date Code Title Description
8141 Disposal/no request for examination